| Literature DB >> 26039059 |
Aruni Seneviratna1, Gek Hsiang Lim2, Anju Devi2, Leonardo P Carvalho3, Terrance Chua4, Tian-Hai Koh4, Huay-Cheem Tan1, David Foo5, Khim-Leng Tong6, Hean-Yee Ong7, A Mark Richards8, Chow Khuan Yew2, Mark Y Chan8.
Abstract
OBJECTIVES: There are conflicting data on the relationship between the time of symptom onset during the 24-hour cycle (circadian dependence) and infarct size in ST-elevation myocardial infarction (STEMI). Moreover, the impact of this circadian pattern of infarct size on clinical outcomes is unknown. We sought to study the circadian dependence of infarct size and its impact on clinical outcomes in STEMI.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26039059 PMCID: PMC4454698 DOI: 10.1371/journal.pone.0128526
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Study Flow.
Of 25,058 patients registered in the Singapore Myocardial Infarction Registry (SMIR), 6,710 who were diagnosed with STEMI and with known times of symptom onset were selected for analysis.
Baseline characteristics of patients.
| Time of symptom onset | Midnight–6:00 A.M. | 6:00 A.M.–Noon | Noon–6:00 P.M. | 6:00 P.M.–Midnight | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| Number of cases (%) | 1429 | (21.3) | 2102 | (31.3) | 1572 | (23.4) | 1607 | (24.0) | |
| Age (years): Mean (SD) | 60.7 | (12.9) | 60.7 | (13.1) | 60.3 | (13.3) | 59.7 | (12.9) | 0.99 |
| Male (%) | 1153 | (80.7) | 1651 | (78.5) | 1239 | (78.8) | 1290 | (80.3) | 0.99 |
| Chinese (%) | 887 | (62.1) | 1389 | (66.1) | 1032 | (65.7) | 992 | (61.7) | 0.37 |
| Malay (%) | 302 | (21.1) | 350 | (16.7) | 284 | (18.1) | 335 | (20.9) | |
| Indian (%) | 212 | (14.8) | 329 | (15.7) | 230 | (14.6) | 244 | (15.2) | |
| Other (%) | 28 | (2.0) | 34 | (1.6) | 26 | (1.7) | 36 | (2.2) | |
| Current smoker (%) | 630 | (44.1) | 823 | (39.2) | 691 | (44.0) | 715 | (44.5) | 0.04 |
| Hypertension (%) | 873 | (61.1) | 1200 | (57.1) | 869 | (55.3) | 926 | (57.6) | 0.21 |
| Diabetes mellitus (%) | 627 | (43.9) | 799 | (38.0) | 611 | (38.9) | 690 | (42.9) | 0.03 |
| Dyslipidemia (%) | 1076 | (75.3) | 1600 | (76.1) | 1167 | (74.2) | 1210 | (75.3) | 0.99 |
| Past MI (%) | 204 | (14.3) | 252 | (12.0) | 174 | (11.1) | 211 | (13.1) | 0.83 |
| Weekend admission (%) | 396 | (27.7) | 599 | (28.5) | 469 | (29.8) | 522 | (32.4) | 0.41 |
| Anterior STEMI (%) | 790 | (55.3) | 1064 | (50.6) | 819 | (52.1) | 857 | (53.3) | 0.03 |
| Peak CK concentration (IU/L): mean (SD) | 2590.8 | (2839.1) | 2336.3 | (2386.6) | 2526.8 | (2809.7) | 2522.1 | (2645.2) | 0.03 |
a With Bonferroni correction.
Baseline characteristics of patients categorized according to time of symptom onset. Data expressed as mean ± SD for continuous variables, median (range) for skewed data and percentages for categorical variables. Chi-square test was performed for categorical variables, analysis of variance for parametric continuous variables, Wilcoxon Rank-Sum test for non-parametric continuous variables.
Treatment differences among different time intervals.
| Time of symptom onset | Midnight–6:00A.M. | 6:00A.M.–Noon | Noon–6:00P.M. | 6:00P.M.–Midnight | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Aspirin (%) | 1229 | (86.7) | 1859 | (89.0) | 1369 | (87.9) | 1408 | (88.4) | 0.99 |
| P2Y12 antagonist (%) | 1221 | (86.2) | 1844 | (88.3) | 1357 | (87.2) | 1402 | (88.1) | 0.99 |
| Beta-blocker (%) | 1086 | (76.6) | 1629 | (78.0) | 1190 | (76.4) | 1233 | (77.5) | 0.99 |
| ACE/ARB (%) | 998 | (70.4) | 1451 | (69.5) | 1034 | (66.4) | 1142 | (71.7) | 0.34 |
| Lipid lowering therapy/statin (%) | 1240 | (87.5) | 1876 | (89.9) | 1378 | (88.5) | 1416 | (88.9) | 0.99 |
|
| |||||||||
| Aspirin (%) | 1193 | (83.5) | 1821 | (86.6) | 1343 | (85.5) | 1376 | (85.7) | 0.99 |
| P2Y12 antagonist (%) | 1186 | (83.1) | 1790 | (85.2) | 1313 | (83.6) | 1352 | (84.2) | 0.99 |
| Beta-blocker (%) | 622 | (43.6) | 1005 | (47.8) | 715 | (45.5) | 745 | (46.4) | 0.99 |
|
| |||||||||
| Door-to-balloon time: Mean (SD | 1.8 | (1.2) | 1.6 | (1.0) | 1.6 | (0.9) | 1.8 | (1.1) | 0.07 |
| Door-to-balloon time: Median (range), hours | 1.5 | (0.1–11.0) | 1.4 | (0.3–11.6) | 1.4 | (0.2–11.7) | 1.5 | (0.4–10.0) | 0.07 |
| Ischemic time (hours): mean (SD) | 5.9 | (5.3) | 4.6 | (3.8) | 4.4 | (4.0) | 5.9 | (6.1) | 0.68 |
| Ischemic time (hours): median (range) | 4.4 | (0.9–75.6) | 3.6 | (0.4–33.4) | 3.3 | (0.3–37.2) | 3.7 | (0.6–71.9) | 0.68 |
| PCI | 956 | (67.0) | 1540 | (73.3) | 1089 | (69.3) | 1053 | (65.6) | 0.03 |
| CABG | 48 | (3.4) | 53 | (2.5) | 37 | (2.4) | 45 | (2.8) | 0.03 |
a SD = standard deviation
b PCI = Percutaneous coronary intervention
c CABG = coronary artery bypass grafting
Differences in revascularization treatments received by patients categorized according to time of symptom onset. Ischemic and door-to-balloon times were measured from the time of symptom onset and the time of arrival at the emergency department to the time of first device deployment respectively.
Fig 2STEMI Incidence as a function of time of symptom onset.
Bar chart showing number of patients with symptom onset within each of the 4 pre specified time intervals. The peak incidence of symptom onset was observed in the 6:00-noon period (P<0.001).
Fig 3Infarct size as a function of time of symptom onset.
Mean Peak log creatine kinase (CK) concentration of patients with symptom onset within each of the 4 time intervals. Wide bars represent mean concentration and T bars represent standard deviation (SD). The maximum and minimum mean peak logCK concentration was observed with symptom onset from midnight-6:00 A.M. and 6:00 A.M.-noon respectively. Comparison of mean peak logCK across 4 time intervals was performed using the Kruskall-Wallis test followed by a Bonferroni correction (P = 0.03). The difference remained statistically significant after adjusting for the presence of diabetes, infarct location and use of PCI (P = 0.04).
Fig 4Fitted curve of Peak concentration of log (CK) against time of symptom onset.
Non-linear B-splines with 3 internal knots (turning points) between 3:00AM– 6:00AM, 6:00AM– 9:00AM and 6:00PM—9:00PM, centering on mean log peak CK, to assess any potential non-linear relationship between the exposure (time of symptom onset) and outcome of interest (infarct size).
Complications of AMI and clinical outcomes.
| Time of symptom onset | Midnight–6:00A.M. | 6:00A.M.–Noon | Noon–6:00P.M. | 6:00P.M.–Midnight | P-value | ||||
|---|---|---|---|---|---|---|---|---|---|
| LVEF (%) | 35.0%±8.7 | 37.0±8.0 | 36.5±8.7 | 35.6±8.5 | 0.03 | ||||
| Left ventricular systolic dysfunction (%) | 829 | (58.6) | 1081 | (52.0) | 847 | (54.5) | 948 | (59.7) | 0.03 |
| Acute heart failure (%) | 326 | (22.8) | 326 | (15.5) | 271 | (17.2) | 334 | (20.8) | <0.001 |
| Cardiogenic shock (%) | 140 | (15.4) | 149 | (11.8) | 138 | (13.8) | 135 | (13.5) | 0.99 |
| Atrial Fibrillation (%) | 105 | (7.4) | 127 | (6.0) | 118 | (7.5) | 104 | (6.5) | 0.03 |
| VF/sustained VT (%) | 91 | (6.4) | 108 | (5.1) | 101 | (6.4) | 109 | (6.8) | 0.99 |
| Complete heart block (%) | 49 | (3.5) | 77 | (3.7) | 60 | (3.9) | 70 | (4.4) | 0.99 |
| Acute renal failure (%) | 92 | (6.5) | 104 | (5.0) | 91 | (5.9) | 90 | (5.7) | 0.99 |
| Cerebrovascular accident (%) | 22 | (1.6) | 21 | (1.0) | 25 | (1.6) | 29 | (1.8) | 0.99 |
| 1-year mortality (%) | 298 | (20.9) | 346 | (16.5) | 292 | (18.6) | 276 | (17.2) | 0.03 |
| 30-day mortality (%) | 237 | (16.6) | 274 | (13.0) | 241 | (15.3) | 220 | (13.7) | 0.03 |
| Reinfarction (%) | 25 | (2.8) | 27 | (2.1) | 18 | (1.8) | 25 | (2.5) | 0.78 |
a Left ventricular systolic dysfunction defined as LVEF < 50% on echocardiography
b Acute heart failure defined as Killip class ≥ II.
Short- and long-term clinical outcomes categorized according to time of symptom onset.
Fig 5Long-term survival as a function of time of symptom onset.
Survival curves out to 4.5 years of follow up shown above and Kaplan-Meier estimates of 12-month survival shown below.
Multivariable logistic regression analysis of clinical outcomes.
| Time of symptom onset | 1-year mortality | 30-day mortality | Reinfarction | Left ventricular systolic dysfunction | Killip Class (I vs. II—IV) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | |
| Midnight–6:00 A.M. | 1 (reference group) | 0.7 | 1 (reference group) | 0.47 | 1 (reference group) | 0.85 | 1 (reference group) | 0.07 | 1 (reference group) | 0.001 |
| 6:00 A.M.–Noon | 0.73 (0.35–1.49) | 0.93 (0.53–1.64) | 1.16 (0.50–2.70) | 0.83 (0.67–1.02) | 0.69 (0.57–0.82) | |||||
| Noon–6:00 P.M. | 1.07 (0.47–2.44) | 1.47 (0.79–2.75) | 0.81 (0.30–2.21) | 1.05 (0.83–1.33) | 0.73 (0.61–0.88) | |||||
| 6:00 P.M.–Midnight | 0.77 (0.35–1.71) | 1.20 (0.64–2.23) | 1.24 (0.50–3.05) | 1.02 (0.80–1.29) | 0.88 (0.74–1.05) | |||||
A multivariable logistic regression model adjusting for diabetes prevalence, infarct location (anterior vs. non-anterior) and performance of percutaneous coronary intervention (PCI) was used to determine if time of symptom onset was an independent predictor of secondary outcomes.